Schedule 13G ownership disclosure

Enanta Pharmaceuticals Inc

COMMON STOCK, Par Value $0.01 Per Share · CUSIP: 29251M106

Event date: 2024-02-22

Reporting persons may disclose overlapping interests. Their amounts are shown individually and are not added into a filing total.

Filing-level shares
Unavailable
Percent of class
Unavailable
  • Krensavage Asset Management, LLC

    Shares: 1,086,024.00 · Class: 5.1%

  • KRENSAVAGE PARTNERS LP

    Shares: 979,910.00 · Class: 4.6%

  • Krensavage Partners Too, LP

    Shares: 106,114.00 · Class: 0.5%

Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.

Source: SEC EDGAR filing

Filing metadata

Accession number
0001609251-24-000004
Form type
SCHEDULE 13G
Filer
ENANTA PHARMACEUTICALS INC
CIK
CIK 1177648
Filed
Feb 27, 2024
Reporting period
Feb 22, 2024
Description
Schedule 13G beneficial ownership

Explore SEC Filings Hub